FutureCure Health raises Rs 104 Cr led by Carnelian Asset Management

FutureCure Health, a healthcare technology company focused on super-speciality care, has mopped up Rs 104 crore ($11.5 million) in a funding round led by Carnelian Asset Management LLP, with participation from other investors.

The fundraising follows an earlier $4 million round in 2022 backed by Kotak Alternate Asset Management, RVCF Ventures, and Unicorn India Ventures.

The fresh funds will be utilised to expand access to the diagnosis and treatment of vertigo, FutureCure Health said in a press release.

Co-founded in 2015 by Rajneesh Bhandari and Anita Bhandari, FutureCure runs NeuroEquilibrium, its wholly owned subsidiary and a chain of vertigo and dizziness diagnostic and rehabilitation clinics. Unlike conventional approaches, NeuroEquilibrium focuses on identifying the root cause of vertigo, whether arising from the inner ear, the brain, or balance pathways, enabling targeted treatment rather than temporary relief.

NeuroEquilibrium addresses a critical global gap in access to specialised neuro-otology care. By integrating advanced diagnostic systems, cloud-based remote platforms, and deep-tech innovation, it scales precision care beyond traditional urban centres, impacting patients worldwide while advancing cutting-edge medical technology.

As NeuroEquilibrium scales across hospitals in India and globally and expands into chronic lifestyle diseases such as migraine and diabetes, it focuses on using technology to bridge the shortage of specialist doctors. Precise, scalable diagnostics can democratise super-speciality healthcare and act as a force multiplier for better outcomes.

Working closely with hospitals, ENT clinics, and neurology centres, NeuroEquilibrium claims to operate over 300 clinics in India and 16 other countries and has enabled diagnosis and treatment for over 150,000 patients, significantly improving long-term outcomes.